Back to Search
Start Over
Current and future nanoparticle vaccines for COVID-19
- Source :
- EBioMedicine, Vol 74, Iss , Pp 103699- (2021)
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.
Details
- Language :
- English
- ISSN :
- 23523964
- Volume :
- 74
- Issue :
- 103699-
- Database :
- Directory of Open Access Journals
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.bf14de8d1459d8d7e587ed362bfa6
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.ebiom.2021.103699